Serum myostatin levels in chronic heart failure

Elisabet Zamora, Rafael Simó, Josep Lupón, Amparo Galán, Agustín Urrutia, Beatriz González, Dolores Mas, Vicente Valle

Producció científica: Contribució a una revistaArticleRecercaAvaluat per experts

20 Cites (Scopus)

Resum

Muscle wasting is common in advanced heart failure. Myostatin is an important modulator of muscle catabolism. We measured serum levels of myostatin and its propeptide in patients with chronic heart failure and analyzed their relationships with clinical parameters and prognosis. The study included 70 patients: 30 in New York Heart Association (NYHA) functional class I-II and 40 in class III-IV. Their mean ejection fraction was 32%±12%. The mean follow-up time was 17.9±1.3 months. Thirteen patients (18.6%) died. No correlation was found between myostatin and myostatin propeptide levels. Nor was the myostatin or myostatin propeptide level correlated with age, sex, left ventricular ejection fraction, symptom duration, or the level of N-terminal probrain natriuretic peptide (NT-proBNP) or tumor necrosis factor-alpha receptor type-2 (TNFα R2). Moreover, no relationship was observed between the myostatin or myostatin propeptide level and NYHA functional class or mortality, in contrast to the relationships found with NT-proBNP (P<.001 and P<.001, respectively) and TNFα R2 (P=.001 and P=.005, respectively) levels. In conclusion, there was no relationship between the myostatin or myostatin propeptide level and any parameter of disease severity or prognosis in patients with chronic heart failure. © 2010 Sociedad Española de Cardiología.
Idioma originalEnglish
Pàgines (de-a)992-996
RevistaRevista Espanola de Cardiologia
Volum63
Número8
DOIs
Estat de la publicacióPublicada - 1 d’ag. 2010

Fingerprint

Navegar pels temes de recerca de 'Serum myostatin levels in chronic heart failure'. Junts formen un fingerprint únic.

Com citar-ho